LIVN - リバノバ （LivaNova PLC）

LivaNova (LIVN) on Friday announced the resignation of its CEO and preliminary Q1 revenue that was above consensus. Read more here.

https://www.investing.com/news/pro/livanova-plc-receives-investment-bank-analyst-rating-update-3052312

WILMINGTON, DE / ACCESSWIRE / March 28, 2023 / Transparency Market Research Inc. - The pulmonary valve replacement market was valued at USD 1.0 Bn in 2022 and is projected to surpass USD 1.6 Bn by 2031 with CAGR of 4.9%. Rise in number of transcatheter heart valve replacement procedures in developed countries in the past few years has helped augment the pulmonary valve replacement market size. Advancements in diagnosis of pulmonary valve disorders are likely to bolster the market development. Request for a Sample PDF Report with Latest Industry Insights: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85497 Surge in prevalence of congenital heart diseases (CHD) in adults in several countries is likely to bolster the demand for pulmonary valve replacement procedures. Rapid increase in number of adults with CHD is driving the need for revised guidelines on the management of adult CHD. These guidelines should focus on risk assessment and the type of interventions that would prove effective in the treatment of the disease.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, May 3, 2023 at 1 p.m. L…

A share of LivaNova PLC (NASDAQ:LIVN) closed at $41.20 per share on Friday, down from $42.77 day before. While LivaNova PLC has underperformed by -3.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LIVN fell by -43.68%, with highs and lows ranging from $88.00 to $41.82, […]

Major players in the cardiac valve market are LivaNova PLC, Abbott Laboratories , Colibri Heart Valve LLC, TTK HealthCare Limited, Artivion Inc, JenaValve Technology Inc, Edwards Lifesciences Corporation, Lepu Medical Technology Co Ltd, Braile Biomédica, Foldax Inc, Sorin SpA, Neovasc Inc, The RUA Life Sciences group, Translumina Therapeutics Private Limited and On-X Life Technologies. Major players in the cardiac valve market are LivaNova PLC, Abbott Laboratories , Colibri Heart Valve LLC, TTK HealthCare Limited, Artivion Inc, JenaValve Technology Inc, Edwards Lifesciences Corporation, Lepu Medical Technology Co Ltd, Braile Biomédica, Foldax Inc, Sorin SpA, Neovasc Inc, The RUA Life Sciences group, Translumina Therapeutics Private Limited and On-X Life Technologies.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received a close-out letter from the U.S. Food and Drug Administration (FDA) for the War…

ReportsnReports publishes the report titled Cardiopulmonary Autotransfusion Devices that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes

NEW YORK, Dec. 6, 2022 /PRNewswire/ -- Major players in the cardiac pacemakers market are Medtronic Plc, Lepu Medical Technology Co, Abbott Inc, Biotronik SE & Co KG, Boston Scientific Corporation, LivaNova PLC, Medico SRL, Osypka AG, Oscor Inc, MicroPort Scientific Corporation,…

ReportsnReports publishes the report titled Cardiopulmonary Autotransfusion Devices that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes

NEW YORK, Dec. 6, 2022 /PRNewswire/ -- Major players in the cardiac pacemakers market are Medtronic Plc, Lepu Medical Technology Co, Abbott Inc, Biotronik SE & Co KG, Boston Scientific Corporation, LivaNova PLC, Medico SRL, Osypka AG, Oscor Inc, MicroPort Scientific Corporation,…

As of Thursday, LivaNova PLC’s (NASDAQ:LIVN) stock closed at $52.13, up from $51.35 the previous day. While LivaNova PLC has overperformed by 1.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LIVN fell by -39.36%, with highs and lows ranging from $89.69 to $41.82, whereas the […]

LivaNova (LIVN) has received US FDA 510(K) clearance for extracorporeal membrane oxygenation (ECMO) for LifeSPARC, its advanced circulatory support pump and controller system.The…

The following slide deck was published by LivaNova PLC in conjunction with their 2022 Q3 earnings call.